Expertise in
23
conditions

Dr. Jared R. Brosch

Neurology
Iu Health Physicians/Iu North Hospital
11725 Illinois St Ste 275, 
Carmel, IN 
Accepting New Patients
Offers Telehealth
Expertise in
23
conditions
Iu Health Physicians/Iu North Hospital
11725 Illinois St Ste 275, 
Carmel, IN 

Overview

Jared Brosch is a Neurologist practicing medicine in Carmel, Indiana.

Dr. Brosch is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Lewy Body Dementia (LBD), and Cerebellar Degeneration.

He is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 9 clinical trials. Dr. Brosch is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in IN

Hospital Affiliations

Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health Ball Memorial Hospital
Iu Health West Hospital
Indiana University Health North Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Iu Health Physicians/Iu North Hospital
11725 Illinois St Ste 275, Carmel, IN 46032
Other Locations
Office
355 W 16th St Ste 3200, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Drug, Other
Study Drug: Donanemab
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: TAK-071
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

49 Total Publications

Interconnected influences of diet, gut microbiome, and metabolome on cognition across three metabolomics platforms.
Interconnected influences of diet, gut microbiome, and metabolome on cognition across three metabolomics platforms.
Journal: Research square
Published: June 22, 2026
Similar Doctors
Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Indiana University Medical Center

545 Barnhill Dr, 
Indianapolis, IN 
 (12.9 miles away)
317-274-8800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Martin Farlow is a Neurologist practicing medicine in Indianapolis, Indiana. Dr. Farlow is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Gerstmann-Straussler-Scheinker Syndrome, and Frontotemporal Dementia. Dr. Farlow is currently accepting new patients.

Expertise in
44
conditions
Expertise in
44
conditions
Referral may be required

Indiana University Psychiatric Associates Inc.

355 W 16th St, 
Indianapolis, IN 
 (12.1 miles away)
317-963-7000
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Pascuzzi is a Neurologist practicing medicine in Indianapolis, Indiana. He has been practicing medicine for over 47 years. Dr. Pascuzzi is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal and Bulbar Muscular Atrophy, and Thymectomy. Dr. Pascuzzi is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Office

250 N Shadeland Ave, 
Indianapolis, IN 
 (14.6 miles away)
317-948-5450
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Liana Apostolova is a Neurologist practicing medicine in Indianapolis, Indiana. Dr. Apostolova is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Alzheimer's Disease, Dementia, Primary Amyloidosis, and Developmental Dysphasia Familial. Dr. Apostolova is currently accepting new patients.

Frequently Asked Questions about Dr. Jared R. Brosch

How do I make an appointment with Dr. Jared R. Brosch?

You can book an appointment with Dr. Jared R. Brosch by calling their office at 317-948-5450. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jared R. Brosch a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jared R. Brosch is classified as an Elite expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jared R. Brosch specialize in?

While Dr. Jared R. Brosch is a Neurology, they have specific expertise in Alzheimer's Disease, Dementia, and Lewy Body Dementia (LBD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Jared R. Brosch participate in research or clinical trials?

Yes. Dr. Jared R. Brosch has published 49 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Jared R. Brosch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jared R. Brosch accept my insurance?

Dr. Jared R. Brosch accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-948-5450 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Brosch's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 91 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile